J & J faces thousands of Risperdal lawsuits

More than 5,000 lawsuits have been filed against Johnson & Johnson for failure to warn doctors and consumers that Risperdal can cause boys to grow large breasts, a condition known as gynecomastia.

Risperdal Litigation

At least 1,500 Risperdal cases have been consolidated in Pennsylvania on behalf of individuals who allege the drug caused excessive male breast growth and other complications. Complex litigation with multiple plaintiffs takes time. First filed in 2010, Risperdal bellwether trials are currently underway in the Philadelphia Court of Common Pleas.

One case now before a jury was brought by a Risperdal user who was prescribed the drug off-label as an 11-year-old boy to treat symptoms associated with Tourette’s syndrome. The plaintiff, who required surgery to remove excess breast tissue that allegedly resulted from his use of Risperdal, claims that Johnson & Johnson and its Janssen Pharmaceutical unit made millions of dollars by improperly promoting unapproved pediatric use of the drug. The lawsuit also alleges the pharmaceutical companies did not adequately warn doctors and consumers about the association between Risperdal and the development of gynecomastia in boys.

Risperdal in the News

Overall, media coverage of this case has been sporadic at best. However, the Huffington Post has released a massive 58,000-word, 15-chapter “DocuSerial,” which casts a bright light on the far-reaching effects of Risperdal. As part of their extensive reporting, the publication released the following short film, entitled, “The Boy with 46-DD Breasts.” The documentary follows the story of Austin Pledger, who developed “large pendulous breasts” as a teen after he began taking the drug for autism at age eight.


The Boy With 46-DD Breasts from HuffPost Highline on Vimeo.

Jury awards $2.5 million in Risperdal lawsuit

Boys and young men who develop gynecomastia after taking Risperdal may be eligible to receive financial compensation for both physical and emotional injuries. In February 2015, Pledger was awarded $2.5 million after a judge declared J & J failed to warn the drug could cause breast development. While some Risperdal cases have gone to trial, others settle out of court. Although the terms are confidential, settlements typically include money for surgery, ongoing medical care and counseling.

UPDATE (11/9/15) – In the third bellwether Risperdal trial in Pennsylvania, a jury ordered Johnson & Johnson to pay $1.75 million to a Maryland man who developed female breasts while taking Risperdal. The plaintiff, who had been prescribed Risperdal off-label when he was 9-years-old to treat symptoms associated with autism, was awarded compensatory damages for disfigurement and mental anguish.

Do lawsuits hurt big pharma?

Damages are awarded in a civil lawsuit to “make the plaintiff whole.” In some cases, punitive damages are also awarded to punish the defendant and (hopefully) deter future misdeeds. Unfortunately, most lawsuits against pharmaceutical manufacturers don’t make any difference in how these behemoths do business. Why? Big pharma has very deep pockets, as evidenced by the following statement, which Johnson & Johnson filed with the Securities and Exchange Commission in 2013—a year when their pharmaceutical segment achieved sales of $28.1 billion.

In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings . . . is not expected to have a material adverse effect on the Company’s financial position.

So, it seems that although Johnson & Johnson—and many of the top pharmaceutical corporations—face thousands of expensive lawsuits, they’ll be just fine. Too bad the same can’t be said for the thousands of hapless victims of corporate greed.



Brill, Steven. “America’s Most Admired Lawbreaker.” The Huffington Post, September 15, 2015.

Johnson & Johnson. 2013 Annual Report. New Brunswick, NJ: Johnson & Johnson, 2013.

Kristof, Nicholas. “When Crime Pays: J&J’s Drug Risperdal.” The New York Times, September 17, 2015.

Wasserman, Emily. “J&J slapped with 1.75M verdict in Risperdal breast growth case.” FiercePharma, November 10, 2015.




Is Your Doctor Giving You Fake Drugs?

It seems that even doctors can fall prey to the same counterfeit drug scams that have plagued consumers. We received an email today, which announced the FDA has launched a new website, warning health care professionals about a growing trend: Fake drug distributors.

“There is a growing network of rogue wholesale drug distributors selling potentially unsafe drugs in the U.S. market,” read the email. The new website,“Know Your Source,” advises healthcare professionals to only purchase  prescription drugs from licensed wholesale distributors.

Too little, too late?

FDA: Know your sourceWhile we applaud the efforts of the FDA to combat this problem – fake drugs undoubtedly pose a serious risk to patients – the problem is anything but new. In a letter dated December 19, 2012, the FDA notified medical practices they may have received unapproved medications. According to the FDA, “These medications may be counterfeit, contaminated, improperly stored and transported, ineffective, and/or unsafe.”

In fact, consumers have been warned about counterfeit drugs for years, with “Canadian” distributors at the forefront of the problem. So, how is it that doctors are unaware of these scams—many of which appear to be rather obvious. For example, one flyer on the website warns doctors to “Beware of Offers Too Good to be True” and that, “Aggressive marketing tactics and deep discounts on prescription drugs may indicate that the products are stolen, counterfeit, substandard, or unapproved.”

The FDA also shared these rather common-sense signs that a drug may be fake:

  • The label is not in English.
  • The packaging looks slightly different from the FDA-approved product
  • The product names differs from the name of the FDA-approved drug
  • The dosing recommendations are unfamiliar
  • Safety information or warnings are missing
  • The dosage form or administration is different

How can we, as consumers, protect ourselves?

When a doctor administers medication in the office, you probably won’t see the packaging. A nurse may hand you a pill or give you a shot. So how can you be sure they received the medicine from a reliable distributor? ASK.

Don’t be shy about asking your doctor questions regarding your medication

  • Ask where the medication came from. While it is not a guarantee, medicines are generally safe if your doctor purchased them directly from the manufacturer or a state-licensed wholesale drug distributor.
  • Ask for a copy of the package insert, detailing the possible side effects and other important safety information.
  • Tell your doctor if you experience unusual side effects or if the medication doesn’t seem to be working. These may be signs of counterfeit medication. 

Remember, while most prescription drugs in the United States are safe, it is important to be a vocal advocate for yourself and your loved ones.




FDA warns doctors to beware fake drug distributorsModern Healthcare /Associated Press, September 23, 2104

The Possible Dangers of Buying Medicines over the Internet” FDA.gov, January 26, 2011.

The Trouble with Low T Treatments

Have you noticed the ever-increasing collection of commercials targeting men with low testosterone, or “Low T?” Much like the advertising for Viagra and other ED medications, these ubiquitous sales pitches prey on the insecurities of mature men with promises of increased vitality, improved muscle mass, alleviating depression, and improved sexual performance.

But for some men, these drugs come at steep price.

A recent study published in the Journal of the American Medical Association indicates testosterone treatments may increase risks of heart attack, stroke and death in men. A previous study had to be cancelled in 2009 due to “an increased risk of adverse cardiovascular events.”

What is Low T?

Testosterone is an androgen, or male hormone, produced in the testicles and regulated by glands in the brain. Low testosterone, also known as androgen deficiency or hypogonadism, can result from problems in the testicles or the brain. This is different from the normal decrease in testosterone levels in men over 30, which is a normal part of the aging process and does not necessarily require treatment.


Testosterone Replacement Therapy (TRT) has been proven effective, but for whom? Low T diagnosis can be difficult since the symptoms of hypogonadism are arguably vague and may develop over time. Adding to the problem are aggressive marketing campaigns by pharmaceutical companies, which have resulted in blockbuster sales for drug makers like AbbVie and Eli Lilly. Reports indicate that the percentage of men being treated for “Low T” has almost quadrupled since 2000, reaching $1.6 billion in U.S. sales in 2011.

The Endocrine Society recommends testosterone treatment for men who are diagnosed as having low testosterone based on both symptoms and blood tests showing indisputably low testosterone levels, but some doctors are prescribing testosterone replacement therapy to healthy men who want to boost their libido, energy and strength.

However, testosterone treatment “offers no proven benefits for healthy men,” says Dr. Adriane Fugh-Berman, of Georgetown University Medical Center. “Low T syndrome is invented by pharmaceutical companies to sell treatment products.”



Testosterone treatments linked to heart risksAP/USA Today, November 5, 2013.

Too many men take testosterone when they don’t need it” by Endocrine Society, The Washington Post, January 13, 2014.

Popular ‘low T’ therapy divides the medical field” by Laura Ungar, The (Louisville, Ky.) Courier-Journal, June 12, 2013.

Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels” JAMA. 2013;310(17):1829-1836. doi:10.1001/jama.2013.280386.

“Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline” The Endocrine Society®, The Journal of Clinical Endocrinology & Metabolism, June 2010, Vol. 95(6):2536–2559.

Glaxo to End Some Payments to Doctors

In a surprising announcement, pharmaceutical giant GlaxoSmithKline revealed they will soon put an end to a common industry practice of paying doctors and other health professionals to promote their drugs. The company said it will stop paying doctors to endorse its products at speaking engagements and no longer base the pay of sales representatives on how many prescriptions are written.

A fistfull of twentiesWhile some may applaud their efforts, it does appear somewhat suspect in light of the recent bribery charges levied by the Chinese government claiming Glaxo bribed doctors and government officials in order to boost sales. The move also comes just prior to the implementation of legislation, which requires such payments to be made available to the public under the Physician Payment Sunshine Act (Section 6002 of the Patient Protection and Affordable Care Act.)

Also known as Open Payments, the Act was created to provide greater transparency around the financial relationships of manufacturers, physicians, and teaching hospitals. It requires the following information to be submitted annually to the Centers for Medicare and Medicaid Services (CMS):

  • Payments or other transfers of value by manufacturers of covered drugs, devices, biologicals, and medical supplies to physicians and teaching hospitals
  • Certain ownership or investment interests held by physicians or their immediate family members
  • Payments or other transfers of value made to physician owners or investors by certain group purchasing organizations
  • The Centers for Medicare and Medicaid will collect data, aggregate it, and publish it on a public website.

For patients, Glaxo’s decision is a step in the right direction, but conflicts of interest remain. The New York Times reports that Glaxo will “continue to provide what the company described in a statement as ‘unsolicited, independent educational grants’ to continue educating doctors about their products.” Doctors will also continue to receive consulting fees from Glaxo for market research.

So, is this move part of a new, socially responsible corporate culture for Glaxo, or just an effort to stop the bleeding? It’s hard to tell. Bloomberg Newsweek reporter Diane Brady seems to share our skepticism:

It’s hard to look like an innovator when your company has paid a $3 billion fine in the U.S. and is accused of paying another half-billion dollars in bribes to China.

In a perfect world, doctors would prescribe medications to their patients based on unbiased, independent research weighing the risks and benefits for each individual. Hospitals and medical professionals would not receive kick-backs or be subjected high-pressure sales pitches promoting off-label use by pharmaceutical representatives and Big Pharma would not inundate the public with direct-to-consumer advertisements.

Sadly, we don’t live in that world (at least not yet) and sometimes baby steps are better than no steps at all.



Glaxo Says It Will Stop Paying Doctors to Promote Drugs” by Katie Thomas, The New York Times, December 16, 2013.

Is GlaxoSmithKline Playing Defense—or the Opposite?” by Diane Brady, Bloomberg Businessweek, December 18, 2013.

China Charges Drug Company with Bribery

Pharmaceutical giant GlaxoSmithKline has been accused of bribing government officials and doctors to boost its drug sales in China. According to Chinese officials, the British drugmaker was involved in a conspiracy involving hundreds of millions of dollars that has spanned several years.

Chinese authorities claim that senior Glaxo executives used travel agencies to launder money that was ultimately used for bribes. Travel agencies reportedly enticed GSK executives by offering cash, luxurious travel accommodations, and even hiring prostitutes for “sexual bribery.” The agencies allegedly invented fictitious corporate meetings that required travel; the budget would then be used to bribe doctors to prescribe GSK drugs. Gao Feng, a Chinese ministry official said Glaxo and the travel agencies have exchanged three billion Chinese yuan ($489 million) since 2007.

China Widens Probe of Sexual Bribes and Glaxo ExecsBloomberg TV, YouTube, July 16, 2013.

Damage Control

While these allegations appear salacious and damaging to GSK, even if the drugmaker is penalized by the Chinese, the corporation isn’t likely to suffer any major losses. Media reports put possible fines at $5 -10 million, a drop in the bucket considering GSK’s revenue of $26.4 billion last year. Still, Glaxo officials are clearly trying to mitigate investor worries. They issued a statement that the company finds the allegations “shameful” and that it had put an “immediate stop” to the use of the named travel agencies. The company further commented that it shares the desires of the Chinese government and is cooperating with the investigation.

Just the Tip of the Iceberg?

Charges of bribery in China are nothing new. Many contend the country is rife with corruption and see investigations such as this as posturing by the Chinese government to appear strong and keep drug prices by outside companies low. Indeed, rumors are already circulating that four other multinational pharmaceutical corporations are also being investigated for similar violations.

So, is bribery simply the price of doing business in China, or is this case symptomatic of wide-spread corruption within the industry as a whole? Well, just last year Glaxo plead guilty and paid $3 billion dollars to resolve federal and civil charges in the United States. Their offenses included aggressive off-label marketing, withholding safety data, and bribing doctors… what do you think?


Glaxo Used Travel Firms for Bribery, China Says” by David Barboza, The New York Times, July 15, 2013.

First Non-hormonal Drug Approved by FDA for Hot Flashes

If you’ve been suffering from hot flashes and night sweats, but were reluctant to take medications with hormones, you now have an alternative. The FDA announced that it has approved Brisdelle, the first non-hormonal drug to treat moderate to severe hot flashes. That’s great news, right? Well, sort of. It turns out the drug isn’t really new at all. Brisdelle is simply a lower dose of paroxetine, the same drug contained in the anti-depressants Paxil and Pexeva.

The New York Daily News reports that paroxetine “has been prescribed off-label by doctors for years as a treatment for menopausal symptoms.” Despite this widespread use, earlier this year, the FDA’s independent advisory committee voted not to approve Brisdelle because there was insufficient evidence to support that the benefits of the drug outweighed the risks. Nevertheless, the FDA approved Brisdelle last month.

“There are a significant number of women who suffer from hot flashes associated with menopause and who cannot or do not want to use hormonal treatments,” said Hylton V. Joffe, M.D. M.M.Sc., of the FDA. However the agency admitted, “The mechanism by which Brisdelle reduces hot flashes is unknown.”

SSRIs can be dangerous

Paroxetine belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). According to the Mayo Clinic, these drugs work by affecting naturally occurring chemical messengers (neurotransmitters), which are used to communicate between brain cells. SSRIs block the reabsorption (reuptake) of the neurotransmitter serotonin in the brain. While doctors don’t understand how, the drugs seem to help alleviate symptoms.

Like all SSRIs, Paroxetine will carry a Boxed Warning of an increased risk of suicide. Additional labeled warnings include a possible reduction in the effectiveness of tamoxifen (used to treat breast cancer), an increased risk of bleeding, nausea, headache, fatigue and vomiting.

Patients who abruptly stop taking SSRIs may experience what’s known as antidepressant discontinuation syndrome. Its symptoms include insomnia, chronic nausea, flu-like symptoms and hyperarousal (a heightened state of psychological and physical tension).

SSRIs may pose risks during pregnancy

Although most women who suffer from hot flashes no longer have their period, they can also occur during perimenopause — the process of change that leads up to menopause — which may start as early as your 30’s. If you are or may become pregnant, we caution you to speak to your doctor before taking an SSRI such as Brisdelle.

SSRIs have also been linked to persistent pulmonary hypertension in newborn babies, according to articles published through the Mayo Clinic. Studies have also linked the drugs to severe birth defects, increased risk of miscarriage, and low birth weight.


First nonhormonal treatment for hot flashes, Brisdelle, approved by FDA” by Tracy Miller, New York Daily News, July 2, 2013.

“FDA approves the first non-hormonal treatment for hot flashes associated with menopause” FDA News Release, June 28, 2013.

Illegal Online Pharmacies Shut Down

Faced with mounting medical bills, American consumers have flocked to the internet in search of “Canadian Pharmacies” selling bargain-priced prescription drugs. What they may not know is that the drugs may actually come from overseas and many of the websites are illegal, selling dangerous unapproved medications.

The FDA released a statement yesterday stating that it has shut down 1,677 websites and seized $41 million of illegal drugs in a massive international sting operation.  Dubbed “Operation Pangea VI,” the global task force encompassed agencies from 99 different countries, the largest internet-based action of its kind. The effort targeted nearly 10,000 websites and sought to “identify the makers and distributors of illegal drug products and medical devices and remove these products from the supply chain.”

Many of the websites displayed fake credentials, including counterfeit licenses and certifications. Consumers were duped into purchasing drugs that were neither brand name nor FDA approved. “Illegal online pharmacies put American consumers’ health at risk by selling potentially dangerous products, said John Roth, director of the FDA’s Office of Criminal Investigations.

CNN reports, “Several sites had sleek interfaces and names that could easily be confused with legitimate pharmacy retailers. For example, the FDA shuttered Walgreens-Store.com; the well-known drugstore chain’s website is actually Walgreens.com.”

Learn to Protect Yourself

The FDA warns consumers to be leery of online pharmacies that do not require a prescription, send spam or other unsolicited emails, or offer prices that seem too good to be true. In order to alert the public, the FDA’s “Office of Criminal Investigations Cybercrime Investigations Unit” banner has been placed on seized websites.

For more information, visit www.fda.gov/BeSafeRx‎ — part of a national campaign to raise awareness of the dangers of buying prescription medicines from fake online pharmacies.


Source: “FDA shuts down 1,677 online pharmacies” By Caleb Hellerman, CNN, June 27, 2013.

New Safety Review of Diabetes Drugs

Possible link to cancer

The American Diabetes Association (ADA) has called for an independent safety review of drugs used to control blood sugar for patients with Type 2 Diabetes.  The ADA issued a statement this week asking pharmaceutical companies to “make patient-level data on their products available for an independent review that could help settle the question of whether such therapies contribute to the development of pancreatitis or pancreatic cancer.”

The U.S. Food and Drug Administration (FDA) and European health regulators have been studying unconfirmed reports that these drugs may cause harm to the pancreas, including inflammation and pre-cancerous changes to pancreatic cells.

Pharmaceutical companies agree to cooperate

Drug makers Bristol-Myers, AstraZeneca and Merck all issued statements expressing support for the study. Novo Nordisk representative Alan Moses told Reuters, “In principle, Novo Nordisk absolutely supports working with the other companies, but the final details depend on what specifically is being proposed,” Moses said, adding “it all depends on the credibility of the data that’s being evaluated.”

Pharmaceutical companies have struggled to find medications that treat diabetes without causing serious side effects. 24 million Americans suffer from diabetes. And according to the International Diabetes Federation, the disease affects more than 370 million people worldwide.

The safety review will study patients taking several drugs, including:

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Januvia® (sitagliptin)
    • Onglyza® (saxagliptin)
    • Tradjenta® (linagliptin )
    • Galvus® (vildagliptin) – available in Europe

Glucagon-like Peptide-1 (GLP-1) Agonists

If you or a loved one have experienced any harmful side effects after taking a diabetes treatment, contact a drug injury lawyer at Elk & Elk. Our Ohio product liability attorneys, paralegals, doctor, nurses, investigators and economist will work hard to help you get the compensation you deserve.

Call 1-800-ELK-OHIO or fill out our online case evaluation form for a free consultation. When you choose Elk & Elk for your drug injury claim, there’s never a fee unless we win. Put our experience and resources to work for you.



Drugmakers to cooperate in safety review of diabetes drugs,” by Bill Berkrot, Reuters, June 12, 2013.

“American Diabetes Association Calls for Independent Review of Incretin Therapy,” American Diabetes Association, June 10, 2013.

Comeback for Avandia?

Once the world’s best-selling treatment for type 2 diabetes, GlaxoSmithKline’s Avandia is currently banned in Europe and severely restricted in the U.S – due to an increased risk of heart attack and stroke. But new recommendations from federal health advisors may change things. The New York Times reports, “A panel of experts voted Thursday to loosen restrictions [on Avandia], saying doctors should have more freedom to prescribe it to patients.”

The Food and Drug Administration advisory panel’s members voted after a two-day meeting to consider a new analysis of Avandia’s cardiovascular safety. Of the 26 members in attendance, 13 voted to relax safety restrictions, 7 voted to remove restrictions, 5 to keep them the same, and one panelist voted to withdraw Avandia from the market altogether.

Too little, too late

In 2007, Avandia was linked to possible heart trouble.
In 2007, Avandia was linked to possible heart trouble.

Even if the FDA does loosen restrictions, it may be too late for Glaxo. According to CNBC, panel members agreed that Avandia may never reach its former annual sales of $3.2 billion. “The train has left the station,” said Gerald van Belle, director of the Clinical Trials Center at the University of Washington. Glaxo’s patent on Avandia expired last year. Although another drug company has approval to sell a generic version, it has not done so.

Glaxo has settled a myriad of lawsuits filed by “tens of thousands” of patients who claim Glaxo failed to inform them about safety risks.  And, in an unprecedented case last summer, the drugmaker agreed to pay $3 billion to settle the largest case of healthcare fraud in U.S. history – resolving allegations that they had failed to provide safety data on Avandia to the FDA and had improperly marketed other drugs.

Moving forward

In a statement, Glaxo said it would work with the FDA as it considers any potential changes. Currently, Avandia may only be prescribed as a last resort to those who have not responded to other therapies – about 3000 patients, down from 120,000 before restrictions were put in place. The panel’s recommendation is not binding, but the FDA will take it into consideration when it makes its final decision, no word yet on when that will be.

Call 1-800-ELK-OHIO for a free consultation if you or a loved one has suffered from a dangerous drug or medical device

If you, a loved one or someone you know has been harmed by a recalled drug or defective medical device, you need the help of a proficient, experienced and determined law firm with the experience and resources to prove your case. Give Elk & Elk the opportunity to show you what a difference a law firm with our experience and resources can make in your life. We offer free, no-obligation telephone consultations at 1-800-ELK-OHIO 24 hours a day, seven days a week, 365 days a year. We also offer a no-cost, no-obligation online contact form. With the drug recall attorneys at Elk & Elk, there’s never a fee unless we have a successful outcome for you, and we’re here around the clock.

FDA launches online pharmacy awareness campaign, helps ID licensed websites

For millions of Americans, a large percentage of their monthly budgets must go toward prescription medications. Millions of dollars are spent on prescription drugs each year in our country. Ninety percent of senior citizens and 57 percent of non-senior citizens rely on at least one prescription drug on a daily basis.

Combine these numbers with an estimated 48.6 million Americans who do not have medical insurance and you can see why many Americans face the choice of buying food or buying medication.

These circumstances have forced many to look for alternatives, including online pharmacies. If you do an online search for “online pharmacy” you will find a seemingly endless list of websites offering to sell you all manner of prescription drugs.

But when it comes to buying medicine online, it is important to be very careful. Some Web sites sell medicine that may not be safe to use and could put your health at risk.

Some medicines sold online:

  • are fake (counterfeit or “copycat” medicines)
  • are too strong or too weak
  • have dangerous ingredients
  • have expired (are out-of-date)
  • aren’t FDA-approved (haven’t been checked for safety and effectiveness)
  • aren’t made using safe standards
  • aren’t safe to use with other medicine or products you use
  • aren’t labeled, stored, or shipped correctly

To help battle this growing issue, the U.S. Food and Drug Administration has launched a national campaign to educate consumers about the dangers of buying medicine from fake online pharmacies and help people safely buy medicine online. “FDA BeSafeRx – Know Your Online Pharmacy” seeks to educate consumers and health care professionals about the health risks of buying prescription medicine through fake online pharmacies and to help current and potential online pharmacy consumers to make informed purchasing decisions.

The FDA did a survey recently and found that one in four Americans had bought prescription drugs online. Nearly 30 percent said they were not confident about safely buying prescription drugs on the Internet.

This FDA campaign comes on the heels of an investigation by the National Association of Boards of Pharmacy. The NABP looked into 10,000 websites and discovered that a staggering 97 percent were not in compliance with U.S. pharmacy laws.

If you follow this link, you can click on your state so you can always make sure that the online pharmacy you are researching is:

  • Licensed in the United States
  •  Requires a doctor’s prescription
  • Provides a physical address and telephone number in the United States
  • Offers a licensed pharmacist to answer your questions.

The FDA offers some valuable tips for anyone considering buying their prescription drugs online.

Beware of online pharmacies that:

  • Allow you to buy drugs without a prescription from your doctor
  • Offer deep discounts or cheap prices that seem too good to be true
  • Send spam or unsolicited email offering cheap drugs
  • Are located outside of the United States
  • Are not licensed in the United States

The personal injury lawyers of Elk & Elk want you to be informed of the dangers in buying prescription medications online so you can protect yourself and your loved ones. To find out more about Elk & Elk, visit our website.